Five Prime Therapeutics (NASDAQ:FPRX) had its target price lowered by BMO Capital Markets from $75.00 to $60.00 in a research note issued to investors on Wednesday morning. BMO Capital Markets currently has an outperform rating on the biotechnology company’s stock.
FPRX has been the topic of a number of other reports. Royal Bank of Canada increased their target price on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the company an outperform rating in a research report on Monday, November 6th. BidaskClub downgraded shares of Five Prime Therapeutics from a hold rating to a sell rating in a research report on Saturday, December 9th. Zacks Investment Research downgraded shares of Five Prime Therapeutics from a hold rating to a sell rating in a research report on Thursday, January 25th. Finally, ValuEngine downgraded shares of Five Prime Therapeutics from a hold rating to a sell rating in a research report on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus price target of $55.00.
Five Prime Therapeutics (NASDAQ FPRX) opened at $21.26 on Wednesday. Five Prime Therapeutics has a 52-week low of $17.01 and a 52-week high of $48.87.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.